| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5281 | 2012 |
| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5093 | 2011 |
| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3249 | 2013 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 1587 | 2015 |
| Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 2020 | 547 | 2020 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 424 | 2020 |
| Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with … RJ Motzer, CH Barrios, TM Kim, S Falcon, T Cosgriff, WG Harker, ... Journal of Clinical Oncology 32 (25), 2765-2772, 2014 | 409 | 2014 |
| A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients TW Flaig, DL Gustafson, LJ Su, JA Zirrolli, F Crighton, GS Harrison, ... Investigational new drugs 25, 139-146, 2007 | 390 | 2007 |
| Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ... European urology 66 (5), 815-825, 2014 | 353 | 2014 |
| Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer CG Rusthoven, BL Jones, TW Flaig, ED Crawford, M Koshy, DJ Sher, ... Journal of Clinical Oncology 34 (24), 2835-2842, 2016 | 275 | 2016 |
| Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology PE Spiess, N Agarwal, R Bangs, SA Boorjian, MK Buyyounouski, ... Journal of the National Comprehensive Cancer Network 15 (10), 1240-1267, 2017 | 256 | 2017 |
| NCCN guidelines insights: bladder cancer, version 5.2018 TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the national comprehensive cancer network 16 (9), 1041-1053, 2018 | 252 | 2018 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 250 | 2017 |
| Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer JL Gulley, M Borre, NJ Vogelzang, S Ng, N Agarwal, CC Parker, DW Pook, ... Journal of Clinical Oncology 37 (13), 1051-1061, 2019 | 241 | 2019 |
| A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer TW Flaig, M Glodé, D Gustafson, A van Bokhoven, Y Tao, S Wilson, LJ Su, ... The Prostate 70 (8), 848-855, 2010 | 227 | 2010 |
| EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4–positive solid tumors, including metastatic urothelial carcinoma J Rosenberg, SS Sridhar, J Zhang, D Smith, D Ruether, TW Flaig, ... Journal of Clinical Oncology 38 (10), 1041-1049, 2020 | 217 | 2020 |
| NCCN Guidelines® insights: bladder cancer, version 2.2022: featured updates to the NCCN guidelines TW Flaig, PE Spiess, M Abern, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 20 (8), 866-878, 2022 | 189 | 2022 |
| Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control MA Stinauer, BD Kavanagh, TE Schefter, R Gonzalez, T Flaig, K Lewis, ... Radiation Oncology 6, 1-8, 2011 | 188 | 2011 |
| Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer AM Kamat, TW Flaig, HB Grossman, B Konety, D Lamm, MA O'donnell, ... Nature Reviews Urology 12 (4), 225-235, 2015 | 187 | 2015 |
| Renal cell carcinoma: a review of biology and pathophysiology S Nabi, ER Kessler, B Bernard, TW Flaig, ET Lam F1000Research 7, 2018 | 169 | 2018 |
